Setterwalls advises Immunovia in connection with a rights issue of approximately SEK 100 million

Setterwalls advises Immunovia AB (publ) (“Immunovia”) in connection with a rights issue of shares that will provide Immunovia with proceeds of approximately SEK 100 million before deduction of transaction costs.

Immunovia is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia is listed on Nasdaq Stockholm.